Mabxience

Mabxience company information, Employees & Contact Information

Explore related pages

Related company profiles:

mAbxience is a Spanish-based company specializing in the development, production, and commercialization of biopharmaceuticals. With over a decade of expertise, our mission is clear: to provide accessible, affordable medicines across the globe, aiming to enhance the quality of life by ensuring universal access to high-caliber medicines. With two market-approved products and a robust pipeline in development, we have established a B2B presence in over 100 markets. Alongside this, we have formed a network with more than 30 partners and built a dedicated team of over 1,000 professionals. Our three multi-product facilities, located in Europe and South America, have obtained GMP approval from esteemed regulatory bodies, including the FDA, EMA, and others. Furthermore, as a global biopharmaceutical expert, mAbxience specializes in Contract Development and Manufacturing Organization services (CDMO), utilizing advanced technology and innovative platforms to deliver integrated manufacturing solutions. For more insights into mAbxience, our biosimilars and CDMO business, please visit our website (www.mabxience.com)

Company Details

Employees
1.06K
Founded
-
Address
C/ Manuerl Pombo Angulo, 28,third Floor,switzerland
Phone
+41 91 973 14 23
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Madrid, Madrid
Looking for a particular Mabxience employee's phone or email?

Mabxience Questions

News

mAbxience Announces European Commission Approval of Denosumab Biosimilars - PR Newswire

mAbxience Announces European Commission Approval of Denosumab Biosimilars PR Newswire

Denosumab Biosimilar Earns European Approval in Advanced Malignancies Involving the Bone and Giant Cell Tumors of the Bone - OncLive

Denosumab Biosimilar Earns European Approval in Advanced Malignancies Involving the Bone and Giant Cell Tumors of the Bone OncLive

Pooled analysis of three pharmacokinetic studies comparing biosimilar MB02 and reference bevacizumab - British Pharmacological Society | Journals

Pooled analysis of three pharmacokinetic studies comparing biosimilar MB02 and reference bevacizumab British Pharmacological Society | Journals

Abbott Broadens Access to Cutting-Edge Biosimilars in Key Emerging Markets - Abbott MediaRoom

Abbott Broadens Access to Cutting-Edge Biosimilars in Key Emerging Markets Abbott MediaRoom

Spain’s mAbxience adding another 4kL single-use bioreactor - BioProcess International

Spain’s mAbxience adding another 4kL single-use bioreactor BioProcess International

Biosimilar Business Recap: BI Layoffs; Teva, mAbxience Partnership; Phase 3 Keytruda Biosimilar Trial - Center for Biosimilars

Biosimilar Business Recap: BI Layoffs; Teva, mAbxience Partnership; Phase 3 Keytruda Biosimilar Trial Center for Biosimilars

mAbxience Appoints Jurgen Van Broeck as New CEO - PR Newswire

mAbxience Appoints Jurgen Van Broeck as New CEO PR Newswire

Teva, mAbxience Strike Licensing Deal for Biosimilar Candidate Focused on Multiple Oncology Indications - Pharmaceutical Executive

Teva, mAbxience Strike Licensing Deal for Biosimilar Candidate Focused on Multiple Oncology Indications Pharmaceutical Executive

Teva, forging ahead with new strategy, inks biosimilar deal with Spain's mAbxience - Fierce Pharma

Teva, forging ahead with new strategy, inks biosimilar deal with Spain's mAbxience Fierce Pharma

Teva, mAbxience Expand Collaboration to Include an Additional Oncology Biosimilar - Contract Pharma

Teva, mAbxience Expand Collaboration to Include an Additional Oncology Biosimilar Contract Pharma

Klinge–MS Pharma and Teva–mAbxience biosimilars licence agreements - Generics and Biosimilars Initiative

Klinge–MS Pharma and Teva–mAbxience biosimilars licence agreements Generics and Biosimilars Initiative

Mabxience Allies With Zentiva For European Bevacizumab Launch - Citeline News & Insights

Mabxience Allies With Zentiva For European Bevacizumab Launch Citeline News & Insights

mAbxience Expanding Biosimilar and CDMO Manufacturing Capacity with ABEC 4,000 Liter Single-Use Bioreactor - Business Wire

mAbxience Expanding Biosimilar and CDMO Manufacturing Capacity with ABEC 4,000 Liter Single-Use Bioreactor Business Wire

Abbott, mAbxience Holdings Strike Biosimilars Commercialization Deal - Pharmaceutical Executive

Abbott, mAbxience Holdings Strike Biosimilars Commercialization Deal Pharmaceutical Executive

Keytruda? Opdivo? Teva And mAbxience Broaden Partnership With PD-1 Biosimilar - Citeline News & Insights

Keytruda? Opdivo? Teva And mAbxience Broaden Partnership With PD-1 Biosimilar Citeline News & Insights

Abbott Labs, mAbxience Enter Biosimilars Mfg. Pact - Contract Pharma

Abbott Labs, mAbxience Enter Biosimilars Mfg. Pact Contract Pharma

BPS Publications - British Pharmacological Society | Journals

BPS Publications British Pharmacological Society | Journals

Fresenius Kabi Takes Control Of mAbxience To Bolster Biosimilars - Citeline News & Insights

Fresenius Kabi Takes Control Of mAbxience To Bolster Biosimilars Citeline News & Insights

Cipla–mAbxience partnership in South Africa - Generics and Biosimilars Initiative

Cipla–mAbxience partnership in South Africa Generics and Biosimilars Initiative

mAbxience: Fresenius buys 55% - pharmabiz.net

mAbxience: Fresenius buys 55% pharmabiz.net

Amneal and mAbxience make deal for bevacizumab biosimilar - Generics and Biosimilars Initiative

Amneal and mAbxience make deal for bevacizumab biosimilar Generics and Biosimilars Initiative

Intas Pharmaceuticals Ltd. Announces Licensing Agreement with mAbxience for Etanercept Biosimilar Targeting Autoimmune Diseases - Business Standard

Intas Pharmaceuticals Ltd. Announces Licensing Agreement with mAbxience for Etanercept Biosimilar Targeting Autoimmune Diseases Business Standard

Intas in pact with Spanish drug maker mAbxience to sell biosimilar etanercept in over 150 countries - The Economic Times

Intas in pact with Spanish drug maker mAbxience to sell biosimilar etanercept in over 150 countries The Economic Times

Intas Pharmaceuticals Ltd. Announces Licensing Agreement with mAbxience - ET HealthWorld

Intas Pharmaceuticals Ltd. Announces Licensing Agreement with mAbxience ET HealthWorld

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant